Swoop utilizes real world data to uncover precision, privacy-safe segments of ideal patients so that pharmaceutical companies can engage and educate them about new therapies
CAMBRIDGE, MA. – January 12, 2020 – Swoop, the company driving better patient outcomes through AI-generated digital audiences for the life sciences industry, today announced the industry’s first HIPPA-certified and NAI accredited system of engagement. The system utilizes machine learning, artificial intelligence and longitudinal analysis in conjunction with an enriched, tokenized and granular-level data pool of over 300 million de-identified patients and a behavioral data stream of over 65 billion anonymous consumer transactions to define and uncover exclusive audiences based on client-specific market definitions and strategies. These segments can then be used to fuel optimal cross-channel marketing strategies that engage the ideal patient with the ideal message through the ideal channel, resulting in greater performance over conventional targeting approaches.
“Life sciences companies seek to appeal to particular patient audiences to drive awareness, prove value and increase consumption of their therapies. However, agencies, data providers and technology companies produce broad generic one-size fits all target segments that fail to consider a brand’s specific needs and core therapeutic advantages”, said Ron Elwell, CEO and co-founder of Swoop. “ The result is an undifferentiated message that broadly reaches too many or even the wrong patients. Pharmaceutical companies have been constrained for years by antiquated thinking, processes and systems that produce the same general off the shelf patient profiles. Swoop is changing this.
Backed by a team of experienced data scientists, life sciences experts and digital marketing professionals, Swoop’s precision, privacy-safe target segment of ideal patients are higher in audience quality and can easily be activated for programmatic advertising; social media marketing; website personalization; adressible, connected and linear television; on-demand audio; and terrestrial radio so that pharmaceutical companies can educate patients about disease states and the therapies that could effectively treat their conditions, as well as enable them to become active participants in their medical journey.
Swoop empowers the world’s leading healthcare and life sciences organizations to better educate patients about disease states and the therapies that could effectively treat their conditions, as well as enable them to become active participants in their medical journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement precisely engages ideal patient populations through cross-channel marketing strategies by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data pool of over 300 million de-identified patients and a behavioral data stream of over 65 billion anonymous consumer transactions.
Chief Marketing Officer
Expands the use of artificial intelligence to positively influence health outcomes without sacrificing patient privacy
Company at the forefront of protecting patient privacy without sacrificing ability to improve health outcomes
Driving optimal patient outcomes through RWD-based and AI-generated digital audiences for the pharmaceutical industry.